Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Combinations in Refractory MDS
NCT03259516Phase 2Terminated
- Sponsor
- First Saint Petersburg State Medical University
- Start
- May 2017
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in myelodysplastic syndrome (MDS) (5 arms), sponsored by First Saint Petersburg State Medical University. Primary endpoint: Overall Response Rate at 6 months. Started May 2017; status: terminated.
02
Drugs
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03259516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259516.